SecBot

SecBot
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001743881

BBIO

BridgeBio Pharma, Inc.
$67.25 ▲ +0.51%
Prev close $66.91
Market cap$12.9B
ConsensusStrong Buy
12-mo target$109.10 (+62.2%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (3 insiders)High Impact Filing (7/10)34 New Institutional Positions16 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on BBIO right now — valuation, ownership and activity at a glance.
Market Cap
$12.9B
Cap Size
Large Cap
Analyst Consensus
Strong Buy (90%)
Inst. Holders
50 funds
Inst. Value
$11.1B
Inst. Activity
34 buys / 16 sells
Insider Activity
$0.00 buy / $22.3M sell
Insider Net $
-$22.3M
SEC Reports
16
Press Releases
10
Congressional
4 trades
Price chart 30d -10.8%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
May 8, 2027 fda_pdufa
PDUFA: BBIO — encaleret in autosomal dominant hypocalcemia type 1 (ADH1) — 2027-05-08
FDA target action date 2027-05-08 for BBIO (BridgeBio Pharma, Inc.). Drug: encaleret. Indication: au
Sep 17, 2026 Insider
Kumar Neil sold 8,721 shares
Chief Executive Officer @ $69.01 ($601.9K)
Sep 17, 2026 Insider
Kumar Neil sold 1,279 shares
Chief Executive Officer @ $69.57 ($89.0K)
Aug 31, 2026 SEC
BridgeBio announced a voluntary agreement with the U.S. government to lower drug costs and expand Medicaid access to its
8-K — Impact 4/10
Aug 26, 2026 Press
BridgeBio announced first patient dosed in ASCEND-ATTR, a Phase 3b/4 study of acoramidis in ATTR-CM, designed to assess
Impact 7/10
Aug 22, 2026 SEC
BridgeBio Pharma saw a mixed institutional cluster in Q2 2026, with 33 buyers adding $561.6M in net new positions (led b
INST-CLUSTER — Impact 6/10
Aug 19, 2026 Insider
Kumar Neil sold 1,800 shares
Chief Executive Officer @ $84.69 ($152.4K)
Aug 17, 2026 SEC
KKR Genetic Disorder L.P. is selling 5,000,000 shares of BridgeBio common stock at $78.00 per share in an underwritten s
8-K — Impact 4/10
Analyst ratings buy % -6.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Strong Buy 90% rate it Buy or better · 29 analysts
Strong Buy 6 21% Buy 20 69% Hold 3 10% Sell 0 0% Strong Sell 0 0%
Recent analyst actions
DateFirmActionRatingFirm rating
Sep 10, 2026HC Wainwright & Co.REITERATEBuy 43%
Sep 2, 2026HC Wainwright & Co.REITERATEBuy 43%
Sep 1, 2026MizuhoMAINTAINOutperform 52%
Aug 12, 2026Truist SecuritiesMAINTAINBuy 55%
Aug 12, 2026Canaccord GenuityMAINTAINBuy 47%
Aug 12, 2026JP MorganMAINTAINOverweight 55%
Aug 11, 2026B of A SecuritiesMAINTAINBuy 54%
Aug 11, 2026TD CowenMAINTAINBuy 56%
Aug 11, 2026Morgan StanleyMAINTAINOverweight 55%
Aug 11, 2026Piper SandlerMAINTAINOverweight 54%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 202662030090%
Aug 1, 202661930089%
Jul 1, 202682020093%
Jun 1, 202681920093%
May 1, 202692010097%
Apr 1, 202691910097%
Mar 1, 202681910096%
Feb 1, 202681910096%
Price targets
Where 21 covering analysts think BBIO trades over the next 12 months.
$109.10 +62.2% upside Strong Buy
Current$67.25 Low$80.00 Median$110.00 High$157.00 21 analysts
$80.00$157.00
Analyst rating Strong Buy· 1.5/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
16 SEC filing reports analyzed · 0 bullish, 2 bearish, 5 mixed, 9 neutral · avg impact 4.6/10.Plus 10 press releases.
NEUTRAL8-K4/10
BridgeBio announced a voluntary agreement with the U.S. government to lower drug costs and expand Me
Aug 31, 2026
MIXEDINST-CLUSTER6/10
BridgeBio Pharma saw a mixed institutional cluster in Q2 2026, with 33 buyers adding $561.6M in net
Aug 22, 2026
NEUTRAL8-K4/10
KKR Genetic Disorder L.P. is selling 5,000,000 shares of BridgeBio common stock at $78.00 per share
Aug 17, 2026
NEUTRAL8-K5/10
BridgeBio reported Q2 2026 revenue of $243.7M, more than doubling YoY, driven by $222.4M in Attruby
Aug 10, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
May 8, 2027
fda_pdufa
PDUFA: BBIO — encaleret in autosomal dominant hypocalcemia type 1 (ADH1) — 2027-05-08
FDA target action date 2027-05-08 for BBIO (BridgeBio Pharma, Inc.). Drug: encaleret. Indication: autosomal dominant hypocalcemia type 1 (ADH1). PDUFA
May 7, 2027
fda_pdufa
PDUFA: BBIO — encaleret in autosomal dominant hypocalcemia type 1 (ADH1) — 2027-05-07
FDA target action date 2027-05-07 for BBIO (BridgeBio Pharma, Inc.). Drug: encaleret. Indication: autosomal dominant hypocalcemia type 1 (ADH1). PDUFA
Nov 27, 2026
fda_pdufa
PDUFA: BBIO — BBP-418 in limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) — 2026-11-27
FDA target action date 2026-11-27 for BBIO (BridgeBio Pharma, Inc.). Drug: BBP-418. Indication: limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
Oct 1, 2026
short_volume
Short Volume: BBIO — 58.7% short (0.9M / 1.5M)
Short: 884,203 | Exempt: 613 | TRF Vol: 1,507,045 | Short Ratio: 58.7% | Off-exchange volume (dark pool + OTC)
Sep 28, 2026
short_volume
Short Volume: BBIO — 59.7% short (0.8M / 1.4M)
Short: 825,613 | Exempt: 0 | TRF Vol: 1,382,758 | Short Ratio: 59.7% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$-0.63$-0.87–$-0.4012.3%-4.0%0↑ 7↓$0.3B7
Next Q$-0.43$-0.63–$0.1353.7%+14.0%1↑ 6↓$0.3B7
Current FY$-2.58$-2.91–$-1.8831.7%+3.7%0↑ 8↓$1.0B8
Next FY$0.03$-1.08–$1.31101.1%-82.1%1↑ 6↓$1.7B7
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$-0.629—
7d ago$-0.629—
30d ago$-0.604-0.024
60d ago$-0.468-0.161
90d ago$-0.475-0.153
Institutional ownership
Which big funds own BBIO (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $11.1B total value (148,743,755 shares) as of 2026-Q2. Top holders: NOMURA, Jupiter, FARALLON. Net buying activity: 34 institutions added/increased vs 16 reduced.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
NOMURA ASSET MANAGEMENT CO LTD0$0.000.0%—
Jupiter Topco LLC14,110,278$1.1B9.5%—
FARALLON CAPITAL MANAGEMENT, L.L.C.10,743,063$800.1M7.2%—
BlackRock, Inc.10,287,156$766.2M6.9%TRIM -27.6%
VIKING GLOBAL INVESTORS LP9,949,219$741.0M6.7%—
VANGUARD CAPITAL MANAGEMENT LLC7,898,973$588.3M5.3%—
VANGUARD PORTFOLIO MANAGEMENT LLC7,656,722$570.3M5.2%—
WELLINGTON MANAGEMENT GROUP LLP5,308,924$395.4M3.6%DOUBLED +113.7%
TWO SIGMA INVESTMENTS, LP4,722,185$351.7M3.2%—
STATE STREET CORP4,435,932$330.4M3.0%—
Recent position changes
FundActionPrevCurrentChangeValue
BlackRock, Inc.TRIM14,207,75710,287,156-27.6%$766.2M
WELLINGTON MANAGEMENT GROUP LLPDOUBLED2,483,9535,308,924+113.7%$395.4M
D. E. Shaw & Co., Inc.ADD2,545,4863,633,007+42.7%$270.6M
GEODE CAPITAL MANAGEMENT, LLCTRIM4,918,0303,418,419-30.5%$254.7M
JANE STREET GROUP, LLCADD1,757,6722,934,193+66.9%$218.5M
JPMORGAN CHASE & COADD1,312,2592,397,995+82.7%$173.2M
ADAGE CAPITAL PARTNERS GP, L.L.C.DOUBLED599,0002,252,000+276.0%$167.7M
NORGES BANKNEW—1,693,773—$126.2M
Point72 Asset Management, L.P.NEW—1,525,782—$113.6M
FRONTIER CAPITAL MANAGEMENT CO LLCADD957,9891,373,057+43.3%$102.3M
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
14 insiders, 50 transactions. Net -$22.3M — $0.00 bought, $22.3M sold.
DateInsiderTitleTypeSharesPriceValue
Sep 17, 2026Kumar NeilChief Executive OfficerSELL8,721$69.01$601.9K
Sep 17, 2026Kumar NeilChief Executive OfficerSELL1,279$69.57$89.0K
Aug 19, 2026Kumar NeilChief Executive OfficerSELL1,800$84.69$152.4K
Aug 19, 2026Kumar NeilChief Executive OfficerSELL8,100$83.86$679.3K
Aug 19, 2026Kumar NeilChief Executive OfficerSELL100$85.65$8.6K
Aug 18, 2026Kumar NeilChief Executive OfficerSELL1,900$81.15$154.2K
Aug 18, 2026Kumar NeilChief Executive OfficerSELL14,602$82.99$1.2M
Aug 18, 2026Kumar NeilChief Executive OfficerSELL17,279$82.21$1.4M
Aug 18, 2026Kumar NeilChief Executive OfficerSELL1,199$83.77$100.4K
Aug 16, 2026Apuli MaricelChief Accounting OfficerTAX W/H4,714$79.86$376.5K
Congressional trades
BBIO trades disclosed by members of Congress, with disclosure delay.
1 members · 4 buys / 0 sells
DateMemberPartyChamberTypeAmountAssetDisclosed
Apr 29, 2026Gilbert CisnerosDHOUSEBUY$1,001 - $15,000BRIDGEBIO PHARMA INCMay 11, 2026(13d)
Mar 19, 2026Gilbert CisnerosDHOUSEBUY$1,001 - $15,000BRIDGEBIO PHARMA INCApr 8, 2026(21d)
Mar 18, 2026Gilbert CisnerosDHOUSEBUY$1,001 - $15,000BRIDGEBIO PHARMA INCApr 8, 2026(22d)
Mar 3, 2026Gilbert CisnerosDHOUSEBUY$1,001 - $15,000BRIDGEBIO PHARMA INCApr 8, 2026(37d)
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for BBIO.
Shares short
21,549,349
Settlement Sep 15, 2026
Change vs prior
-1.4%
Semi-monthly cycle
Days to cover
10.5
At avg daily volume
Of shares outstanding
≈11.0%
Estimate — not % of float
All BBIO filing & press-release reports (26)